Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Mini-Review Article

Role of Human Papillomavirus in Various Cancers: Epidemiology, Screening and Prevention

Author(s): Waqas Ahmed, Sumera Zaib*, Sami Ullah, Areej Fatima, Zainab Zaib, Muhammad Abdul Haseeb Azam, Usama Umar, Muhammad Umair Tariq, Rabia Aslam and Imtiaz Khan*

Volume 23, Issue 10, 2023

Published on: 16 March, 2023

Page: [1079 - 1089] Pages: 11

DOI: 10.2174/1389557523666230213140641

Price: $65

Abstract

It is estimated that viral infections contribute 15-20% of all human cancers. Several types of human papillomaviruse (HPV) are related to the development of many cancer types and their treatment. About 200 HPV viruses have been identified, and each type of virus is integrated with a certain type of clinical lesions affecting the areas of skin and mucous membranes. Infections associated with HPV are known to cause multiple cancer types such as uterine cancer, cervical, vaginal carcinoma, and other varieties of carcinomas such as genital and oropharyngeal, penile, and short-lived carcinomas. Most of the HPV types are considered as high-risk mutants that can provoke cervical cancer in females in addition to significant contribution to other cancer types such as anogenital cancer and tumor in head and neck regions. Among them, high risk human papilloma viruses (HR-HPV) subtypes 16 and 18 play a major role in the etiology of cervical cancer worldwide. Although, cervical cancer incidence and fatality rates vary greatly depending on geographical area, it is the leading cause of mortality in women around the world. In addition, it is epidemiologically similar to a sexually transmitted disease of low infectivity. In this review article, the association of HPV with different types of cancers have been explained, but the main focus remains on cervical cancer.

Graphical Abstract

[1]
Morshed, K.; Polz-Gruszka, D. Szymański, M.; Polz-Dacewicz, M. Human papillomavirus (HPV) – structure, epidemiology and pathogenesis. Otolaryngol. Pol., 2014, 68(5), 213-219.
[http://dx.doi.org/10.1016/j.otpol.2014.06.001] [PMID: 25283316]
[2]
Fox, P.A.; Tung, M.Y. Human papillomavirus. Am. J. Clin. Dermatol., 2005, 6(6), 365-381.
[http://dx.doi.org/10.2165/00128071-200506060-00004] [PMID: 16343025]
[3]
Doorbar, J.; Zheng, K.; Aiyenuro, A.; Yin, W.; Walker, C.M.; Chen, Y.; Egawa, N.; Griffin, H.M. Principles of epithelial homeostasis control during persistent human papillomavirus infection and its deregulation at the cervical transformation zone. Curr. Opin. Virol., 2021, 51, 96-105.
[http://dx.doi.org/10.1016/j.coviro.2021.09.014] [PMID: 34628359]
[4]
Schiffman, M.; Doorbar, J.; Wentzensen, N.; de Sanjosé, S.; Fakhry, C.; Monk, B.J.; Stanley, M.A.; Franceschi, S. Carcinogenic human papillomavirus infection. Nat. Rev. Dis. Primers, 2016, 2(1), 16086.
[http://dx.doi.org/10.1038/nrdp.2016.86] [PMID: 27905473]
[5]
Graham, S.V. The human papillomavirus replication cycle, and its links to cancer progression: A comprehensive review. Clin. Sci., 2017, 131(17), 2201-2221.
[http://dx.doi.org/10.1042/CS20160786] [PMID: 28798073]
[6]
Spurgeon, M.; Lambert, P. Human papillomavirus and the stroma: Bidirectional crosstalk during the virus life cycle and carcinogenesis. Viruses, 2017, 9(8), 219.
[http://dx.doi.org/10.3390/v9080219] [PMID: 28792475]
[7]
Khan, S.; Jaffer, N.N.; Khan, M.N.; Rai, M.A.; Shafiq, M.; Ali, A.; Pervez, S.; Khan, N.; Aziz, A.; Ali, S.H. Human papillomavirus subtype 16 is common in Pakistani women with cervical carcinoma. Int. J. Infect. Dis., 2007, 11(4), 313-317.
[http://dx.doi.org/10.1016/j.ijid.2006.06.007] [PMID: 17291804]
[8]
Burk, R.D.; Harari, A.; Chen, Z. Human papillomavirus genome variants. Virology, 2013, 445(1-2), 232-243.
[http://dx.doi.org/10.1016/j.virol.2013.07.018] [PMID: 23998342]
[9]
Wooldridge, T.R.; Laimins, L.A. Regulation of human papillomavirus type 31 gene expression during the differentiation-dependent life cycle through histone modifications and transcription factor binding. Virology, 2008, 374(2), 371-380.
[http://dx.doi.org/10.1016/j.virol.2007.12.011] [PMID: 18237759]
[10]
Lace, M.J.; Isacson, C.; Anson, J.R.; Lörincz, A.T.; Wilczynski, S.P.; Haugen, T.H.; Turek, L.P. Upstream regulatory region alterations found in human papillomavirus type 16 (HPV-16) isolates from cervical carcinomas increase transcription, ori function, and HPV immortalization capacity in culture. J. Virol., 2009, 83(15), 7457-7466.
[http://dx.doi.org/10.1128/JVI.00285-09] [PMID: 19458011]
[11]
Gunasekharan, V.; Haché, G.; Laimins, L. Differentiation-dependent changes in levels of C/EBPβ repressors and activators regulate human papillomavirus type 31 late gene expression. J. Virol., 2012, 86(9), 5393-5398.
[http://dx.doi.org/10.1128/JVI.07239-11] [PMID: 22379085]
[12]
Zheng, Z.M.; Baker, C.C. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front. Biosci., 2006, 11(1), 2286-2302.
[http://dx.doi.org/10.2741/1971] [PMID: 16720315]
[13]
Wang, Z.; Burge, C.B. Splicing regulation: From a parts list of regulatory elements to an integrated splicing code. RNA, 2008, 14(5), 802-813.
[http://dx.doi.org/10.1261/rna.876308] [PMID: 18369186]
[14]
Shkreta, L.; Bell, B.; Revil, T.; Venables, J.P.; Prinos, P.; Elela, S.A.; Chabot, B. Cancer-associated perturbations in alternative pre-messenger RNA splicing. Cancer Treat. Res., 2013, 158, 41-94.
[http://dx.doi.org/10.1007/978-3-642-31659-3_3] [PMID: 24222354]
[15]
Cheunim, T.; Zhang, J.; Milligan, S.G.; McPhillips, M.G.; Graham, S.V. The alternative splicing factor hnRNP A1 is up-regulated during virus-infected epithelial cell differentiation and binds the human papillomavirus type 16 late regulatory element. Virus Res., 2008, 131(2), 189-198.
[http://dx.doi.org/10.1016/j.virusres.2007.09.006] [PMID: 17950949]
[16]
Kajitani, N.; Schwartz, S. Role of viral ribonucleoproteins in human papillomavirus type 16 gene expression. Viruses, 2020, 12(10), 1110.
[http://dx.doi.org/10.3390/v12101110] [PMID: 33007936]
[17]
Chaudhury, A.; Chander, P.; Howe, P.H. Heterogeneous nuclear ribonucleoproteins (hnRNPs) in cellular processes: Focus on hnRNP E1's multifunctional regulatory roles. RNA, 2010, 16(8), 1449-1462.
[http://dx.doi.org/10.1261/rna.2254110] [PMID: 20584894]
[18]
Naarmann, I.S.; Harnisch, C.; Müller-Newen, G.; Urlaub, H.; Ostareck-Lederer, A.; Ostareck, D.H. DDX6 recruits translational silenced human reticulocyte 15-lipoxygenase mRNA to RNP granules. RNA, 2010, 16(11), 2189-2204.
[http://dx.doi.org/10.1261/rna.2211110] [PMID: 20884783]
[19]
de Sanjosé, S.; Diaz, M.; Castellsagué, X.; Clifford, G.; Bruni, L.; Muñoz, N.; Bosch, F.X. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect. Dis., 2007, 7(7), 453-459.
[http://dx.doi.org/10.1016/S1473-3099(07)70158-5] [PMID: 17597569]
[20]
Rai, B.; Bansal, A.; Singh, M.P. Human papillomavirus-associated cancers: A growing global problem. Int. J. Appl. Basic Med. Res., 2016, 6(2), 84-89.
[http://dx.doi.org/10.4103/2229-516X.179027] [PMID: 27127735]
[21]
Tulay, P.; Serakinci, N. The role of human papillomaviruses in cancer progression. J. Cancer Metastasis Treat., 2016, 2(6), 201-213.
[http://dx.doi.org/10.20517/2394-4722.2015.67]
[22]
Day, P.M.; Weisberg, A.S.; Thompson, C.D.; Hughes, M.M.; Pang, Y.Y.; Lowy, D.R.; Schiller, J.T. Human papillomavirus 16 capsids mediate nuclear entry during infection. J. Virol., 2019, 93(15), e00454-19.
[http://dx.doi.org/10.1128/JVI.00454-19] [PMID: 31092566]
[23]
Sapp, M.; Bienkowska-Haba, M. Viral entry mechanisms: Human papillomavirus and a long journey from extracellular matrix to the nucleus. FEBS J., 2009, 276(24), 7206-7216.
[http://dx.doi.org/10.1111/j.1742-4658.2009.07400.x] [PMID: 19878308]
[24]
Doorbar, J.; Quint, W.; Banks, L.; Bravo, I.G.; Stoler, M.; Broker, T.R.; Stanley, M.A. The biology and life-cycle of human papillomaviruses. Vaccine, 2012, 30(S5), F55-F70.
[http://dx.doi.org/10.1016/j.vaccine.2012.06.083] [PMID: 23199966]
[25]
Reinson, T.; Henno, L.; Toots, M.; Ustav, M., Jr; Ustav, M. The cell cycle timing of human papillomavirus DNA replication. PLoS One, 2015, 10(7), e0131675.
[http://dx.doi.org/10.1371/journal.pone.0131675] [PMID: 26132923]
[26]
Roden, R.B.S.; Stern, P.L. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat. Rev. Cancer, 2018, 18(4), 240-254.
[http://dx.doi.org/10.1038/nrc.2018.13] [PMID: 29497146]
[27]
Florin, L.; Sapp, C.; Streeck, R.E.; Sapp, M. Assembly and translocation of papillomavirus capsid proteins. J. Virol., 2002, 76(19), 10009-10014.
[http://dx.doi.org/10.1128/JVI.76.19.10009-10014.2002] [PMID: 12208977]
[28]
Bosch, F.X.; Qiao, Y.L.; Castellsagué, X. CHAPTER 2 The epidemiology of human papillomavirus infection and its association with cervical cancer. Int. J. Gynaecol. Obstet., 2006, 94(S1), S8-S21.
[http://dx.doi.org/10.1016/S0020-7292(07)60004-6] [PMID: 29644633]
[29]
Motoyama, S.; Ladines-Llave, C.A.; Luis Villanueva, S.; Maruo, T. The role of human papilloma virus in the molecular biology of cervical carcinogenesis. Kobe J. Med. Sci., 2004, 50(1-2), 9-19.
[PMID: 15342967]
[30]
Ljubojevic, S.; Skerlev, M. HPV-associated diseases. Clin. Dermatol., 2014, 32(2), 227-234.
[http://dx.doi.org/10.1016/j.clindermatol.2013.08.007] [PMID: 24559558]
[31]
Cubie, H.A. Diseases associated with human papillomavirus infection. Virology, 2013, 445(1-2), 21-34.
[http://dx.doi.org/10.1016/j.virol.2013.06.007] [PMID: 23932731]
[32]
Accardi, R.; Gheit, T. Cutaneous HPV and skin cancer. Presse Med., 2014, 43(12), e435-e443.
[http://dx.doi.org/10.1016/j.lpm.2014.08.008] [PMID: 25451638]
[33]
de Koning, M.N.C.; ter Schegget, J.; Eekhof, J.A.H.; Kamp, M.; Kleter, B.; Gussekloo, J.; Feltkamp, M.C.W.; Bouwes Bavinck, J.N.; Purdie, K.J.; Bunker, C.B.; Proby, C.M.; Meys, R.; Harwood, C.A.; Quint, W.G.V. Evaluation of a novel broad-spectrum PCR-multiplex genotyping assay for identification of cutaneous wart-associated human papillomavirus types. J. Clin. Microbiol., 2010, 48(5), 1706-1711.
[http://dx.doi.org/10.1128/JCM.02122-09] [PMID: 20237103]
[34]
Insinga, R.P.; Dasbach, E.J.; Elbasha, E.H. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmaco. Economics, 2005, 23(11), 1107-1122.
[http://dx.doi.org/10.2165/00019053-200523110-00004] [PMID: 16277547]
[35]
Tardío, J.C.; Bancalari, E.; Moreno, A.; Martín-Fragueiro, L.M. Genital seborrheic keratoses are human papillomavirus-related lesions. A linear array genotyping test study. Acta Pathol. Microbiol. Scand. Suppl., 2012, 120(6), 477-483.
[http://dx.doi.org/10.1111/j.1600-0463.2011.02853.x] [PMID: 22583360]
[36]
Gormley, R.H.; Kovarik, C.L. Human papillomavirus–related genital disease in the immunocompromised host. J. Am. Acad. Dermatol., 2012, 66(6), 867-867.
[http://dx.doi.org/10.1016/j.jaad.2010.12.050] [PMID: 22583721]
[37]
Ishitsuka, Y.; Hanaoka, Y.; Tanemura, A.; Fujimoto, M. Cutaneous squamous cell carcinoma in the age of immunotherapy. Cancers, 2021, 13(5), 1148.
[http://dx.doi.org/10.3390/cancers13051148] [PMID: 33800195]
[38]
Arbyn, M.; de Sanjosé, S.; Saraiya, M.; Sideri, M.; Palefsky, J.; Lacey, C.; Gillison, M.; Bruni, L.; Ronco, G.; Wentzensen, N.; Brotherton, J.; Qiao, Y.L.; Denny, L.; Bornstein, J.; Abramowitz, L.; Giuliano, A.; Tommasino, M.; Monsonego, J. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int. J. Cancer, 2012, 131(9), 1969-1982.
[http://dx.doi.org/10.1002/ijc.27650] [PMID: 22623137]
[39]
Wiest, T.; Schwarz, E.; Enders, C.; Flechtenmacher, C.; Bosch, F.X. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene, 2002, 21(10), 1510-1517.
[http://dx.doi.org/10.1038/sj.onc.1205214] [PMID: 11896579]
[40]
Chatterjee, S.; Chattopadhyay, A.; Samanta, L.; Panigrahi, P. HPV and cervical cancer epidemiology-current status of HPV vaccination in India. Asian Pac. J. Cancer Prev., 2016, 17(8), 3663-3673.
[PMID: 27644600]
[41]
Kocjan, B.J.; Bzhalava, D.; Forslund, O.; Dillner, J.; Poljak, M. Molecular methods for identification and characterization of novel papillomaviruses. Clin. Microbiol. Infect., 2015, 21(9), 808-816.
[http://dx.doi.org/10.1016/j.cmi.2015.05.011] [PMID: 26003284]
[42]
Duensing, S.; Münger, K. Mechanisms of genomic instability in human cancer: Insights from studies with human papillomavirus oncoproteins. Int. J. Cancer, 2004, 109(2), 157-162.
[http://dx.doi.org/10.1002/ijc.11691] [PMID: 14750163]
[43]
Li, K.; Jin, X.; Fang, Y.; Wang, C.; Gong, M.; Chen, P.; Liu, J.; Deng, D.; Ai, J. Correlation between physical status of human papilloma virus and cervical carcinogenesis. J. Huazhong Univ. Sci. Technolog. Med. Sci., 2012, 32(1), 97-102.
[http://dx.doi.org/10.1007/s11596-012-0017-7] [PMID: 22282253]
[44]
Baseman, J.G.; Koutsky, L.A. The epidemiology of human papillomavirus infections. J. Clin. Virol., 2005, 32(S1), 16-24.
[http://dx.doi.org/10.1016/j.jcv.2004.12.008] [PMID: 15753008]
[45]
Gravitt, P.; Winer, R. Natural history of HPV infection across the lifespan: Role of viral latency. Viruses, 2017, 9(10), 267.
[http://dx.doi.org/10.3390/v9100267] [PMID: 28934151]
[46]
Chan, C.K.; Aimagambetova, G.; Ukybassova, T.; Kongrtay, K.; Azizan, A. Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination-review of current perspectives. J. Oncol., 2019, 2019, 1-11.
[http://dx.doi.org/10.1155/2019/3257939] [PMID: 31687023]
[47]
Häfner, N.; Driesch, C.; Gajda, M.; Jansen, L.; Kirchmayr, R.; Runnebaum, I.B.; Dürst, M. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene, 2008, 27(11), 1610-1617.
[http://dx.doi.org/10.1038/sj.onc.1210791] [PMID: 17828299]
[48]
Melsheimer, P.; Vinokurova, S.; Wentzensen, N.; Bastert, G.; Doeberitz, M.K. DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Clin. Cancer Res., 2004, 10(9), 3059-3063.
[http://dx.doi.org/10.1158/1078-0432.CCR-03-0565] [PMID: 15131043]
[49]
Moody, C. Mechanisms by which HPV induces a replication competent environment in differentiating keratinocytes. Viruses, 2017, 9(9), 261.
[http://dx.doi.org/10.3390/v9090261] [PMID: 28925973]
[50]
Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 2015, 136(5), E359-E386.
[http://dx.doi.org/10.1002/ijc.29210] [PMID: 25220842]
[51]
Altobelli, E.; Rapacchietta, L.; Profeta, V.F.; Fagnano, R. HPV ‐vaccination and cancer cervical screening in 53 WHO European Countries: An update on prevention programs according to income level. Cancer Med., 2019, 8(5), 2524-2534.
[http://dx.doi.org/10.1002/cam4.2048] [PMID: 30993902]
[52]
Bruni, L.; Albero, G.; Serrano, B.; Mena, M.; Collado, J.J.; Gómez, D.; Muñoz, J.; Bosch, F.X.; de Sanjosé, S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). In: Human Papillomavirus and Related Diseases in the World; Barcelona, Spain 2021.
[53]
Khatami, M. Book review on cancer research and therapy: Safety concerns for HPV vaccination of young generation-Paid by Obamacare and VP Biden Moonshot Initiative. Glob. Vaccines Immunol., 2016, 1(3), 63-68.
[http://dx.doi.org/10.15761/GVI.1000118]
[54]
Vieth, M.; Quirke, P.; Lambert, R.; Von Karsa, L.; Risio, M. European guidelines for quality assurance in colorectal cancer screening and diagnosis. Annotations of colorectal lesions. Endoscopy, 2012, 44(S03), SE131-SE139.
[http://dx.doi.org/10.1055/s-0032-1309798]
[55]
Cohen, P.A.; Jhingran, A.; Oaknin, A.; Denny, L. Cervical cancer. Lancet, 2019, 393(10167), 169-182.
[http://dx.doi.org/10.1016/S0140-6736(18)32470-X] [PMID: 30638582]
[56]
Bray, F.; Lortet-Tieulent, J.; Znaor, A.; Brotons, M.; Poljak, M.; Arbyn, M. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia. Vaccine, 2013, 31(S7), H32-H45.
[http://dx.doi.org/10.1016/j.vaccine.2013.02.071] [PMID: 24332296]
[57]
Fitzmaurice, C.; Abate, D.; Abbasi, N.; Abbastabar, H. Global burden of disease cancer collaboration. JAMA Oncol., 2019, 5(12), 1749-1768.
[http://dx.doi.org/10.1001/jamaoncol.2019.2996] [PMID: 31560378]
[58]
Behtash, N.; Mehrdad, N. Cervical cancer: Screening and prevention. Asian Pac. J. Cancer Prev., 2006, 7(4), 683-686.
[PMID: 17250453]
[59]
Khatami, M. Cancer; an induced disease of twentieth century! Induction of tolerance, increased entropy and ‘Dark Energy’: loss of biorhythms (Anabolism v. Catabolism). Clin. Transl. Med., 2018, 7(1), 20.
[http://dx.doi.org/10.1186/s40169-018-0193-6] [PMID: 29961900]
[60]
Maeda, H.; Khatami, M. Analyses of repeated failures in cancer therapy for solid tumors: Poor tumor‐selective drug delivery, low therapeutic efficacy and unsustainable costs. Clin. Transl. Med., 2018, 7(1), 11.
[http://dx.doi.org/10.1186/s40169-018-0185-6] [PMID: 29541939]
[61]
Khatami, M. Retracted: Deceptology in cancer and vaccine sciences: Seeds of immune destruction‐mini electric shocks in mitochondria: Neuroplasticity‐electrobiology of response profiles and increased induced diseases in four generations – A hypothesis. Clin. Transl. Med., 2020, 10(8), e215.
[http://dx.doi.org/10.1002/ctm2.215] [PMID: 33377661]
[62]
Schünemann, H.J.Z. GRADE: from grading the evidence to developing recommendations. A description of the system and a proposal regarding the transferability of the results of clinical research to clinical practice. Z. Evid. Fortbild. Qual. Gesundhwes., 2009, 103(6), 391-400.
[http://dx.doi.org/10.1016/j.zefq.2009.05.023] [PMID: 19839216]
[63]
Safaeian, M.; Solomon, D.; Castle, P.E. Cervical cancer prevention--cervical screening: Science in evolution. Obstet. Gynecol. Clin. North Am., 2007, 34(4), 739-760. ix.
[http://dx.doi.org/10.1016/j.ogc.2007.09.004] [PMID: 18061867]
[64]
Ngoma, M.; Autier, P. Cancer prevention: Cervical cancer. Ecancer Med. Sci., 2019, 13, 952.
[http://dx.doi.org/10.3332/ecancer.2019.952] [PMID: 31552125]
[65]
Bragazzi, N.L.; Watad, A.; Amital, H.; Shoenfeld, Y. Debate on vaccines and autoimmunity: Do not attack the author, yet discuss it methodologically. Vaccine, 2017, 35(42), 5522-5526.
[http://dx.doi.org/10.1016/j.vaccine.2017.08.018] [PMID: 28882443]
[66]
Green, E.C.; Halperin, D.T.; Nantulya, V.; Hogle, J.A. Uganda’s HIV prevention success: The role of sexual behavior change and the national response. AIDS Behav., 2006, 10(4), 335-346.
[http://dx.doi.org/10.1007/s10461-006-9073-y] [PMID: 16688475]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy